Form 4: Axsome Therapeutics CFO Receives Performance Stock Units

Axsome Therapeutics CFO Nick Pizzie was granted 8,188 performance stock units contingent upon commercial milestones.

Summary

• Nick Pizzie, Chief Financial Officer of Axsome Therapeutics, Inc., was granted 8,188 performance stock units (PSUs) on April 21, 2026.
• Each PSU represents a contingent right to receive one share of common stock.
• Vesting of these units is tied to the achievement of specific sales and commercial launch milestones.
• The grant is subject to the reporting person's continued service with the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company fundamentals.

Positives

• Alignment of executive compensation with long-term commercial success and sales performance.

Negatives

• Potential for future dilution of existing shareholders upon the vesting and conversion of these units into common stock.

Risks

• Vesting is contingent upon commercial milestones which may not be achieved.
• Continued service requirement creates dependency on executive retention.

Future Outlook

The vesting of the granted units is dependent on the company achieving specific sales and commercial launch milestones in the future.

Management Comments

• Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date.

Industry Context

StockSavvy.ai notes that performance-based equity grants are standard practice in the biotechnology sector to incentivize executives to reach critical commercialization phases for drug pipelines.

Comparison to Industry Standards

• The use of performance-based vesting criteria is consistent with compensation structures at peer mid-cap biopharmaceutical companies.
• Granting equity tied to commercial milestones is a common retention and performance tool in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution if milestones are met and shares are issued.

Next Steps

• Monitoring of commercial milestones to determine if and when the performance stock units vest.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Form 4, Insider Transaction, Performance Stock Units, Executive Compensation